RxDoctor Payments Data

Arlette Martell Muniz, MD

Internal Medicine · Venice, FLNPI 1508207853

Payments from drug & device makers

$3,237in general payments, 2019–2025

Across 164 payments — averaging $19.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$500
  • Novo Nordisk$464
  • Bayer$408
  • Pfizer$299
  • GSK$273
  • Otsuka America Pharmaceutical, Inc.$236
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$3,237100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,237 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$161,296
Medicare patients
319
Services billed
4,650

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban55$53,567
FarxigaDapagliflozin Propanediol38$43,570
JardianceEmpagliflozin28$38,498
MyrbetriqMirabegron32$21,594
OzempicSemaglutide11$19,431
Breo ElliptaFluticasone/Vilanterol24$19,118
MounjaroTirzepatide19$17,654
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$16,560
TradjentaLinagliptin13$11,826
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$10,608
Doxepin Hcl23$4,797
Estradiol31$2,546
Gabapentin46$1,949
Levothyroxine Sodium193$1,689
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$1,508

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$299$54,99677 claims
AstraZenecaFarxiga, Breztri Aerosphere$194$54,17851 claims
GSKBreo Ellipta, Trelegy Ellipta$273$35,67840 claims
Astellas Pharma US IncMyrbetriq$171$21,59432 claims
Novo NordiskOzempic$464$19,43111 claims
Lilly USA, LLCMounjaro$110$17,65419 claims
AbbVieSynthroid$500$78427 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Venice

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →